当前位置: X-MOL 学术Mech. Ageing Dev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A promising biomarker of elevated galanin level in hypothalamus for osteoporosis risk in type 2 diabetes mellitus
Mechanisms of Ageing and Development ( IF 5.3 ) Pub Date : 2020-12-28 , DOI: 10.1016/j.mad.2020.111427
Penghua Fang 1 , Yuqing She 2 , Long Han 3 , Shiwei Wan 3 , Wenbin Shang 3 , Zhenwen Zhang 4 , Wen Min 3
Affiliation  

Type 2 diabetes mellitus (T2DM) and osteoporosis are two major healthcare problems worldwide. T2DM is considered to be a risk factor for osteoporosis. Interestingly, several epidemiological studies suggest that bone abnormalities associated with diabetes may differ, at least in part, from those associated with senile or post-menopausal osteoporosis. The growing prevalence that patients with T2DM simultaneously suffer from osteoporosis, puts forward the importance to discuss the relationship between both diseases, as well as to investigate correlative agents to treat them. Emerging evidences demonstrate that neuropeptide galanin is involved in the pathogenesis of T2DM and osteoporosis. Galanin via activation of central GALR2 increases insulin sensitivity as well as bone density and mass in animal models. The disorder of galanin function plays major role in development of both diseases. Importantly, galanin signaling is indispensable for ΔFosB, an AP1 antagonist, to play the bone mass-accruing effects in the ventral hypothalamic neurons of diabetic models. This review summarizes our and other recent studies to provide a new insight into the multivariate relationship among galanin, T2DM and osteoporosis, highlighting the beneficial effect of galanin on the comorbid state of both diseases. These may help us better understanding the pathogenesis of osteoporosis and T2DM and provide useful clues for further inquiry if elevated galanin level may be taken as a biomarker for both conjoint diseases, and GALR2 agonist may be taken as a novel therapeutic strategy to treat both diseases concurrently.



中文翻译:

下丘脑甘丙肽水平升高与 2 型糖尿病骨质疏松风险的有希望的生物标志物

2 型糖尿病 (T2DM) 和骨质疏松症是全球两大医疗保健问题。T2DM 被认为是骨质疏松症的危险因素。有趣的是,几项流行病学研究表明,与糖尿病相关的骨骼异常可能与与老年或绝经后骨质疏松症相关的骨骼异常至少部分不同。T2DM 患者同时患有骨质疏松症的患病率越来越高,提出了讨论这两种疾病之间的关系以及研究治疗它们的相关药物的重要性。新出现的证据表明,神经肽甘丙肽与 T2DM 和骨质疏松症的发病机制有关。甘丙肽通过激活中央 GALR2 增加动物模型中的胰岛素敏感性以及骨密度和质量。甘丙肽功能障碍在这两种疾病的发展中起主要作用。重要的是,甘丙肽信号对于 ΔFosB(一种 AP1 拮抗剂)在糖尿病模型腹侧下丘脑神经元中发挥骨量增加作用是必不可少的。本综述总结了我们和其他最近的研究,以提供对甘丙肽、T2DM 和骨质疏松症之间多变量关系的新见解,强调甘丙肽对这两种疾病的共病状态的有益作用。这些可能有助于我们更好地了解骨质疏松症和 T2DM 的发病机制,并为进一步探究是否可以将甘丙肽水平升高作为两种联合疾病的生物标志物提供有用的线索,并且可以将 GALR2 激动剂作为一种新的治疗策略来同时治疗这两种疾病. 甘丙肽信号对于 ΔFosB(一种 AP1 拮抗剂)在糖尿病模型腹侧下丘脑神经元中发挥骨量增加作用是必不可少的。本综述总结了我们和其他最近的研究,以提供对甘丙肽、T2DM 和骨质疏松症之间多变量关系的新见解,强调甘丙肽对这两种疾病的共病状态的有益作用。这些可能有助于我们更好地了解骨质疏松症和 T2DM 的发病机制,并为进一步探究是否可以将甘丙肽水平升高作为两种联合疾病的生物标志物提供有用的线索,并且可以将 GALR2 激动剂作为一种新的治疗策略来同时治疗这两种疾病. 甘丙肽信号对于 ΔFosB(一种 AP1 拮抗剂)在糖尿病模型腹侧下丘脑神经元中发挥骨量增加作用是必不可少的。本综述总结了我们和其他最近的研究,以提供对甘丙肽、T2DM 和骨质疏松症之间多变量关系的新见解,强调甘丙肽对这两种疾病的共病状态的有益作用。这些可能有助于我们更好地了解骨质疏松症和 T2DM 的发病机制,并为进一步探究是否可以将甘丙肽水平升高作为两种联合疾病的生物标志物提供有用的线索,并且可以将 GALR2 激动剂作为一种新的治疗策略来同时治疗这两种疾病. 本综述总结了我们和其他最近的研究,以提供对甘丙肽、T2DM 和骨质疏松症之间多变量关系的新见解,强调甘丙肽对这两种疾病的共病状态的有益作用。这些可能有助于我们更好地了解骨质疏松症和 T2DM 的发病机制,并为进一步探究是否可以将甘丙肽水平升高作为两种联合疾病的生物标志物提供有用的线索,并且可以将 GALR2 激动剂作为一种新的治疗策略来同时治疗这两种疾病. 本综述总结了我们和其他最近的研究,以提供对甘丙肽、T2DM 和骨质疏松症之间多变量关系的新见解,强调甘丙肽对这两种疾病的共病状态的有益作用。这些可能有助于我们更好地了解骨质疏松症和 T2DM 的发病机制,并为进一步探究是否可以将甘丙肽水平升高作为两种联合疾病的生物标志物提供有用的线索,并且可以将 GALR2 激动剂作为一种新的治疗策略来同时治疗这两种疾病.

更新日期:2021-01-12
down
wechat
bug